China’s Personalized mRNA Cancer Vaccine Race Accelerates After Moderna and Merck’s Phase 3 Melanoma Success
The personalized cancer vaccine field has reached a major inflection point.
Moderna and Merck announced on August 19, 2026 that their Phase 3 INTerpath-001 trial of intismeran autogene (V940/mRNA-4157) plus KEYTRUDA (pembrolizumab) met both its primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in patients with completely resected high-risk melanoma.
The companies said the combination produced statistically significant and clinically meaningful improvements in both endpoints compared with KEYTRUDA alone.
Intismeran autogene is an individualized neoantigen therapy manufactured specifically for each patient. Tumor and normal tissue are sequenced to identify cancer-specific mutations, computational algorithms select potentially immunogenic neoantigens, and an individualized mRNA construct encoding selected tumor neoantigens is manufactured to stimulate tumor-specific T-cell responses.
The Phase 3 success represents an important validation not merely for one drug, but for the broader personalized cancer-vaccine concept:
tumor sequencing → computational neoantigen prediction → individualized mRNA manufacturing → vaccination → tumor-specific immune response
China remains several years behind Moderna and Merck in clinical development. Nevertheless, a growing group of Chinese biotechnology companies has entered the personalized mRNA cancer-vaccine field, and several candidates have now reached human trials.
Among the most important programs to watch are NeoCura’s XH001, Everest Medicines’ EVM16, Hangzhou Neoantigen Therapeutics’ iNeo-Vac-R01 and Shanghai Xinpu BioTechnology’s XP-004/XP-006.
China’s Leading Personalized mRNA Cancer Vaccine Programs
| Company | Lead Candidate | Principal Clinical Setting | Development Status* | Key Feature |
|---|---|---|---|---|
| NeoCura / Xinhe Bio | XH001 | High-risk solid tumors after surgery; advanced solid tumors | IND-cleared; Phase 1 recruiting | AI-driven neoantigen selection; postoperative strategy |
| Everest Medicines | EVM16 | Advanced/recurrent solid tumors | Phase 1; human data reported | Neoantigen-specific T-cell responses reported in 8/9 initial patients |
| Hangzhou Neoantigen Therapeutics | iNeo-Vac-R01 | Digestive cancers; postoperative biliary malignancies | Phase 1 / Phase 1/2 | Increasing focus on recurrence prevention |
| Shanghai Xinpu BioTechnology | XP-004 / XP-006 | Postoperative pancreatic cancer; R/R B-cell lymphoma | Early Phase 1 / Phase 1 | Solid and hematological cancer programs |
| Stemirna Therapeutics | Personalized neoantigen mRNA program | Advanced NSCLC and esophageal cancer | Early clinical; status uncertain | One of China’s earlier personalized mRNA vaccine developers |
| Shanghai Regenelead Therapies | Personalized neoantigen mRNA vaccine | Resected pancreatic cancer | Early Phase 1 registered; status uncertain | Vaccine + PD-L1 blockade + chemotherapy |
Development stages reflect publicly available information reviewed through August 29, 2026. Some programs are investigator-initiated trials (IITs), and registry information for certain older studies has not recently been updated.
NeoCura: XH001 Emerges as One of China’s Leading Personalized mRNA Vaccines
NeoCura (Xinhe Bio) has emerged as one of the most important Chinese companies to watch in personalized cancer vaccination.
Its flagship clinical candidate is XH001, an AI-driven personalized tumor neoantigen mRNA vaccine.
XH001 is designed individually for each patient. Tumor samples undergo high-throughput sequencing to identify mutations, while patient-specific HLA information is combined with NeoCura’s proprietary NeoCura AI ALPINE platform to select candidate neoantigens with high predicted immunogenicity.
The selected neoantigens are encoded into an individualized mRNA vaccine intended to induce tumor-specific CD8+ cytotoxic T-cell and CD4+ helper T-cell responses.
XH001 Moves Into Formal IND-Stage Development
XH001 reached an important regulatory milestone in 2025.
According to NeoCura’s announcement, XH001 received clearance in China to enter clinical development in June 2025.
The company subsequently initiated a multicenter Phase 1 clinical program in patients with solid tumors at high risk of recurrence following radical surgery.
The corresponding Phase 1 study, NCT07594964, is listed on ClinicalTrials.gov as recruiting and includes major Chinese oncology centers such as Peking Union Medical College Hospital and Peking University Cancer Hospital.
Approximately 48 patients are planned for enrollment.
The study evaluates safety and tolerability, neoantigen-specific immune responses and clinical outcomes including:
- recurrence-free survival;
- local recurrence-free survival;
- distant metastasis-free survival; and
- overall survival.
This makes XH001 particularly interesting following Moderna and Merck’s Phase 3 melanoma success.
XH001 Is Moving Toward the Same Therapeutic Concept as Intismeran
The strategic similarity between XH001 and intismeran may ultimately be more important than their considerable difference in clinical maturity.
INTerpath-001 evaluated personalized vaccination after complete surgical resection, when patients remained at high risk of recurrence but had relatively low residual tumor burden.
NeoCura is now pursuing a conceptually similar strategy: surgically remove macroscopic disease and then use individualized vaccination to generate T cells capable of recognizing and eliminating microscopic residual cancer cells before recurrence.
XH001 also has earlier investigator-initiated clinical experience.
An exploratory XH001 study, NCT05940181, evaluated the vaccine together with the PD-1 inhibitor sintilimab in patients with advanced solid tumors.
The newer IND-stage postoperative Phase 1 program, however, provides a better indication of XH001’s current clinical-development strategy.
Overall, XH001 deserves to be considered one of China’s leading personalized mRNA cancer-vaccine candidates.
Everest Medicines: EVM16 Produces Encouraging Human Immunogenicity Data
If XH001 represents one of China’s most strategically interesting personalized mRNA programs, Everest Medicines’ EVM16 currently provides some of the clearest publicly disclosed human proof-of-mechanism data.
EVM16 is an individualized therapeutic mRNA cancer vaccine developed using Everest’s proprietary EVER-NEO-1 AI-based neoantigen prediction algorithm.
Each vaccine is designed around mutations unique to an individual patient’s tumor and can encode dozens of predicted tumor neoantigens.
The personalized mRNA is formulated using lipid nanoparticle technology and is intended to generate neoantigen-specific tumor-killing T cells.
Everest dosed the first patient with EVM16 in March 2025 in the EVM16CX01 first-in-human study in patients with advanced or recurrent solid tumors.
8 of 9 Patients Developed Neoantigen-Specific T-Cell Responses
At AACR 2026, Everest reported initial clinical results from nine patients treated with EVM16.
The most striking finding involved immunogenicity:
Eight of nine patients developed neoantigen-specific T-cell responses.
The company also reported an apparent dose-dependent relationship.
Safety appeared encouraging in the small initial dataset, with no reported dose-limiting toxicities and predominantly low-grade treatment-related adverse events.
There were also preliminary signs of antitumor activity.
One heavily pretreated patient with gastroesophageal-junction cancer achieved a confirmed partial response, while two additional patients achieved stable disease.
The sample is far too small to establish efficacy. Nevertheless, demonstrating that computationally selected neoantigens can generate measurable patient-specific T-cell responses represents important proof of mechanism.
According to Everest Medicines’ latest corporate updates, the company has subsequently advanced EVM16 into expansion cohorts and outlined further Phase 1b development.
Everest is also developing EVM14, an off-the-shelf tumor-associated-antigen mRNA cancer vaccine. EVM14 is important to Everest’s broader mRNA oncology platform but is conceptually different from individualized vaccines such as EVM16, XH001 and intismeran autogene.
Hangzhou Neoantigen Therapeutics: iNeo-Vac-R01 Moves Toward the Adjuvant Setting
Another Chinese developer worth watching is Hangzhou Neoantigen Therapeutics, which is developing iNeo-Vac-R01.
iNeo-Vac-R01 is an individualized mRNA therapeutic vaccine encoding tumor neoantigens selected specifically for each patient.
A Phase 1 study, NCT06019702, is evaluating iNeo-Vac-R01 in patients with advanced digestive-system malignancies.
The study incorporates dose escalation and expansion and evaluates safety, feasibility, immunogenicity and preliminary antitumor efficacy.
Importantly, investigators are evaluating neoantigen-specific T-cell responses in addition to conventional oncology measures including objective response rate, disease-control rate, progression-free survival and overall survival.
Moving Into Postoperative Biliary Cancer
Potentially more significant is the newer Phase 1/2 study NCT07368803, which evaluates iNeo-Vac-R01 following radical surgery for biliary malignancies.
The study began in 2025 and is listed as recruiting.
This represents another example of Chinese personalized mRNA vaccine developers shifting toward postoperative recurrence prevention.
That shift may prove crucial.
A personalized vaccine potentially faces a more favorable biological environment when tumor burden is minimal and vaccine-induced T cells need to eliminate microscopic residual disease rather than overcome a large, established and immunosuppressive tumor.
The Moderna/Merck melanoma result substantially strengthens the rationale for this strategy.
Shanghai Xinpu BioTechnology: XP-004 and XP-006 Broaden the Personalized mRNA Strategy
Shanghai Xinpu BioTechnology has established another noteworthy personalized mRNA cancer-vaccine pipeline through collaborations with Chinese academic medical centers.
Its programs are particularly interesting because individualized vaccination is being explored in both solid tumors and hematological malignancies.
XP-004 Targets Postoperative Pancreatic Cancer
XP-004 is being evaluated in NCT06496373, an Early Phase 1 study involving patients who have undergone radical surgery for pancreatic cancer but cannot tolerate postoperative chemotherapy.
The personalized mRNA vaccine encodes patient-specific tumor neoantigens and is combined with immune checkpoint inhibition.
The study evaluates antigen-specific CD4+ and CD8+ T-cell responses as well as recurrence and survival outcomes.
Preliminary findings from the program were also presented at ASCO 2026.
Pancreatic cancer represents a particularly ambitious target because of its highly immunosuppressive tumor microenvironment and historically limited responsiveness to immunotherapy.
The postoperative setting, however, could provide a more favorable opportunity for vaccine-generated immunity than advanced metastatic pancreatic cancer.
XP-006 Takes Personalized mRNA Vaccination Into Lymphoma
Xinpu is also expanding the concept beyond solid tumors.
XP-006 is an individualized mRNA cancer vaccine being developed for relapsed or refractory B-cell non-Hodgkin lymphoma.
The Phase 1 XP-006 study, NCT07334574, is designed to assess multiple dose levels and evaluate neoantigen-specific CD4+ and CD8+ T-cell responses as well as clinical endpoints including ORR, complete response rate, duration of response, PFS and OS.
This approach differentiates Xinpu from many Chinese personalized vaccine companies concentrating almost exclusively on solid tumors.
Taken together, XP-004 and XP-006 suggest that Xinpu is attempting to establish a broader personalized mRNA platform rather than a single-product program.
Stemirna: An Early Chinese mRNA Pioneer With Less-Certain Current Status
Shanghai-based Stemirna Therapeutics was among China’s earliest companies to pursue mRNA therapeutics and personalized cancer vaccination.
Its clinical study NCT03908671 evaluates an individualized neoantigen-encoding mRNA vaccine in patients with advanced esophageal cancer and non-small-cell lung cancer.
The study began as early as 2019, making Stemirna one of the earlier Chinese companies to bring personalized mRNA cancer vaccination into human testing.
However, the ClinicalTrials.gov record has not been updated for several years and currently carries an uncertain status.
Without more recent clinical or corporate disclosures, it would therefore be premature to place Stemirna alongside actively progressing programs such as XH001, EVM16 and iNeo-Vac-R01.
Regenelead Explores Personalized mRNA Vaccination After Pancreatic Cancer Surgery
Shanghai Regenelead Therapies has collaborated with Fudan University Shanghai Cancer Center on another individualized mRNA vaccine strategy.
The registered Early Phase 1 study NCT06156267 is designed to investigate a personalized neoantigen mRNA vaccine together with the PD-L1 antibody adebrelimab and sequential mFOLFIRINOX chemotherapy following surgical resection of pancreatic adenocarcinoma.
Approximately 30 patients were planned.
The biological rationale is notable: remove the primary tumor surgically, identify patient-specific neoantigens from the tumor and use subsequent vaccination and immunotherapy to eradicate residual malignant clones before they establish recurrent disease.
However, the clinical-trial record has not been updated recently.
The program therefore warrants monitoring but currently appears less advanced than China’s leading active candidates.
Which Chinese Personalized mRNA Cancer Vaccines Are Leading?
Based on currently available clinical and regulatory evidence, four programs stand out.
NeoCura — XH001
Why it stands out: XH001 has progressed from earlier investigator-initiated research into formal IND-stage development. Its recruiting Phase 1 study specifically targets patients at high risk of recurrence following radical surgery.
What to watch: manufacturing turnaround time, safety, neoantigen-specific T-cell responses and eventually RFS and DMFS.
Everest Medicines — EVM16
Why it stands out: Everest has produced some of the clearest human proof-of-mechanism data among Chinese developers, including neoantigen-specific T-cell responses in eight of the first nine patients reported.
What to watch: expansion-cohort data and progression into larger Phase 1b/Phase 2 studies.
Hangzhou Neoantigen Therapeutics — iNeo-Vac-R01
Why it stands out: development is moving from advanced gastrointestinal malignancies into the postoperative setting, bringing the strategy increasingly close to the therapeutic model validated by Moderna and Merck.
What to watch: postoperative immunogenicity and recurrence data.
Shanghai Xinpu — XP-004 / XP-006
Why it stands out: Xinpu is developing personalized mRNA vaccination across both solid and hematological malignancies.
What to watch: XP-004 pancreatic cancer data and clinical progression of XP-006.
Moderna/Merck vs. China’s Leading Programs
| Candidate | Developer | Personalized? | Major Current Setting | Development Maturity |
|---|---|---|---|---|
| Intismeran autogene (V940) | Moderna/Merck | Yes | Adjuvant melanoma | Positive Phase 3 |
| XH001 | NeoCura | Yes | Postoperative high-risk solid tumors | Phase 1 recruiting |
| EVM16 | Everest Medicines | Yes | Advanced/recurrent solid tumors | Phase 1; initial human data |
| iNeo-Vac-R01 | Hangzhou Neoantigen Therapeutics | Yes | GI cancers/postoperative biliary cancer | Phase 1 / Phase 1/2 |
| XP-004 | Shanghai Xinpu | Yes | Postoperative pancreatic cancer | Early Phase 1 |
| XP-006 | Shanghai Xinpu | Yes | R/R B-cell NHL | Phase 1 program |
| Personalized vaccine program | Stemirna | Yes | Advanced NSCLC/esophageal cancer | Early clinical; status uncertain |
| Personalized mRNA vaccine | Regenelead | Yes | Postoperative pancreatic cancer | Early Phase 1 registered |
No Chinese personalized mRNA cancer vaccine has yet reached late-stage development, much less produced randomized Phase 3 evidence comparable with intismeran.
But the technological gap may be considerably smaller than the clinical-stage gap suggests.
Why Moderna/Merck’s Phase 3 Success Matters for China
The INTerpath-001 result changes the development thesis around personalized mRNA cancer vaccines.
Previously, developers had demonstrated that personalized neoantigen vaccines could generate immune responses. The much harder question was whether those immune responses could translate into clinically meaningful reductions in cancer recurrence.
The positive Phase 3 INTerpath-001 results provide the strongest validation yet of the approach.
For Chinese companies, three lessons appear particularly important.
1. The Postoperative Setting Could Be Critical
Several Chinese programs originally concentrated on heavily pretreated advanced cancers.
Now XH001, iNeo-Vac-R01, XP-004 and Regenelead’s pancreatic program are exploring vaccination following surgery.
This could represent an important strategic evolution.
When macroscopic disease has been removed, vaccine-generated T cells need to control microscopic residual disease rather than penetrate and eradicate large established tumors.
2. Neoantigen Prediction Could Become a Major Competitive Advantage
mRNA manufacturing itself may eventually become increasingly standardized.
The harder problem is determining which mutations should actually be encoded into each patient’s vaccine.
A tumor can contain hundreds or thousands of mutations, but only a fraction may generate neoantigens that are effectively processed, presented by the patient’s HLA molecules and recognized by therapeutically useful T cells.
Consequently, computational platforms such as NeoCura AI ALPINE and Everest’s EVER-NEO-1 could ultimately prove as strategically important as the mRNA manufacturing technology itself.
3. Manufacturing Speed and Cost Will Matter
Unlike conventional drugs, personalized cancer vaccines cannot simply be mass-produced and stored until patients need them.
The process may involve:
tumor resection/biopsy → sequencing → mutation identification → HLA typing → neoantigen prediction → vaccine design → mRNA synthesis → formulation → quality control → patient dosing
Every additional week matters when treating a patient at substantial risk of cancer recurrence.
Companies capable of compressing this process while maintaining pharmaceutical-grade quality could therefore gain an important competitive advantage.
Could China Have a Manufacturing Advantage?
Personalized cancer vaccination is unusually compatible with several strengths of China’s emerging biotechnology ecosystem.
The country has substantial capabilities in genomic sequencing, artificial intelligence, clinical oncology, mRNA manufacturing and increasingly sophisticated drug-delivery technologies.
China also has large patient populations concentrated at major oncology centers, potentially facilitating disease-specific clinical studies.
If Chinese companies can successfully industrialize individualized manufacturing, they may eventually be able to reduce the cost of personalized vaccination.
That could become crucial because personalized cancer vaccines inherently have more complicated manufacturing economics than conventional biologics or off-the-shelf drugs.
The long-term competition may therefore involve not simply which vaccine works best, but which company can manufacture an effective individualized vaccine fastest, most reliably and at the lowest cost.
Not Every mRNA Cancer Vaccine Will Succeed
The Moderna/Merck Phase 3 success should not be interpreted as evidence that personalized mRNA vaccines will work equally well across all cancers.
Melanoma is highly immunogenic and frequently carries a substantial mutational burden. It is already one of the tumor types most responsive to checkpoint inhibition.
Pancreatic cancer, by comparison, has a highly immunosuppressive tumor microenvironment. Other gastrointestinal malignancies may present similarly difficult biological challenges.
The effectiveness of personalized vaccination could therefore vary substantially according to tumor mutational burden, neoantigen quality, HLA presentation, immune-cell infiltration, tumor microenvironment, residual disease burden, timing of vaccination, previous therapy and sensitivity to checkpoint inhibition.
The ultimate winners may therefore not necessarily be the companies that were first to develop an mRNA platform.
They may instead be the developers that identify the right neoantigens, right cancer types, right disease setting and right combination therapy.
Outlook: XH001 and EVM16 Lead an Emerging Chinese Field
China’s personalized mRNA cancer-vaccine sector remains early, but it has progressed considerably beyond the conceptual stage.
NeoCura’s XH001 has emerged as one of China’s leading formal development programs following Chinese regulatory clearance and initiation of a recruiting Phase 1 study in patients at high risk of recurrence after radical surgery. Its AI-driven neoantigen-selection platform and focus on postoperative recurrence prevention make it particularly relevant following Moderna and Merck’s melanoma success.
Everest Medicines’ EVM16, meanwhile, has produced some of China’s most compelling publicly disclosed human proof-of-mechanism data, including neoantigen-specific T-cell responses in eight of the first nine patients reported.
Behind them, Hangzhou Neoantigen Therapeutics’ iNeo-Vac-R01 and Shanghai Xinpu’s XP-004/XP-006 provide additional clinical shots on goal.
China remains years behind Moderna and Merck in clinical validation.
But INTerpath-001 has addressed perhaps the biggest question hanging over the entire field: whether an individualized mRNA neoantigen vaccine can improve clinically meaningful outcomes in a large randomized cancer trial.
At least in melanoma, the answer is now yes.
For China’s biotech industry, the question has therefore shifted from “Can personalized mRNA cancer vaccines work?” to a much more consequential question:
Which Chinese company can turn the concept into a scalable, clinically validated and commercially viable cancer therapy?
That race is only beginning.
References & Links
- Merck & Moderna — Phase 3 INTerpath-001 Results
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of RFS and DMFS in Patients With High-Risk Melanoma. August 19, 2026.
https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/ - Moderna — Oncology and Individualized Neoantigen Therapy
https://www.modernatx.com/ - NeoCura — XH001 Personalized Tumor Neoantigen Vaccine
https://www.neocura.com.cn/doc_29747400.html - NeoCura — XH001 Clinical Development and NeoCura AI ALPINE Platform
https://www.neocura.com.cn/doc_30252722.html - ClinicalTrials.gov — XH001 Phase 1, NCT07594964
https://clinicaltrials.gov/study/NCT07594964 - ClinicalTrials.gov — XH001 + Sintilimab, NCT05940181
https://clinicaltrials.gov/study/NCT05940181 - Everest Medicines — EVM16 First Patient Dosed
https://www.everestmedicines.com/news/mrnaevm16/8d51d56f-b856-47bd-86e1-61551cb9841b - Everest Medicines — EVM16 and mRNA Pipeline
https://www.everestmedicines.com/ - ClinicalTrials.gov — iNeo-Vac-R01, NCT06019702
https://clinicaltrials.gov/study/NCT06019702 - ClinicalTrials.gov — iNeo-Vac-R01 Postoperative Biliary Cancer Study, NCT07368803
https://clinicaltrials.gov/study/NCT07368803 - ClinicalTrials.gov — XP-004, NCT06496373
https://clinicaltrials.gov/study/NCT06496373 - Journal of Clinical Oncology — XP-004, ASCO 2026
https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.2509 - ClinicalTrials.gov — XP-006, NCT07334574
https://clinicaltrials.gov/study/NCT07334574 - ClinicalTrials.gov — Stemirna Personalized Neoantigen mRNA Vaccine, NCT03908671
https://clinicaltrials.gov/study/NCT03908671 - ClinicalTrials.gov — Regenelead Personalized mRNA Vaccine, NCT06156267
https://clinicaltrials.gov/study/NCT06156267 - Center for Drug Evaluation (CDE), National Medical Products Administration of China
https://www.cde.org.cn/
